Skip to content

Arvinas ARVN Total Revenue

Total Revenue at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$6.25M-66.1%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$34.37M+55.5%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$4.21M-95.0%
Immunome logo
ImmunomeIMNM
$0-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$17M-39.3%
Nuvation Bio logo
Nuvation BioNUVB
$83.23M+2,599%

Segments

By segment

See full
Reportable Segment$15.6M-91.7%

Other financials

Income statement

See full
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's total revenue?
Arvinas (ARVN) reported total revenue of $15.6M in Q1 2026.
How has Arvinas's total revenue changed year-over-year?
Arvinas's total revenue decreased by 91.7% year-over-year, from $188.8M to $15.6M.
What is the long-term trend for Arvinas's total revenue?
Over 3 years (2021 to 2025), Arvinas's total revenue has grown at a 69.9% compound annual growth rate (CAGR), from $53.5M to $262.6M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.